Phreesia, Inc.

  • Market Cap: Small Cap
  • Industry: Software Products
  • ISIN: US71944F1066
USD
20.55
0.17 (0.83%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

238.57 k

Shareholding (Apr 2025)

FII

16.53%

Held by 104 FIIs

DII

31.87%

Held by 57 DIIs

Promoter

1.74%

How big is Phreesia, Inc.?

22-Jun-2025

As of Jun 18, Phreesia, Inc. has a market capitalization of $1.52 billion, with net sales of $434.53 million and a net loss of $42.71 million over the latest four quarters. Shareholder's funds are $264.81 million, and total assets amount to $388.53 million.

As of Jun 18, Phreesia, Inc. has a market capitalization of 1,522.57 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 434.53 million for the latest four quarters, while the net profit for the same period was a loss of 42.71 million.<BR><BR>As of Jan 25, the reporting period shows that Phreesia, Inc. has shareholder's funds amounting to 264.81 million and total assets of 388.53 million.

Read More

What does Phreesia, Inc. do?

22-Jun-2025

Phreesia, Inc. is a U.S.-based healthcare software company specializing in patient intake and payment solutions, with recent net sales of $116 million and a market cap of approximately $1.52 billion. The company reported a net loss of $4 million and has a negative return on equity of -16.06%.

Overview:<BR>Phreesia, Inc. is a United States-based healthcare software company that provides a suite of applications for managing the patient intake process and payment solutions, operating within the Software Products industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 116 Million (Quarterly Results - Apr 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Apr 2025) <BR>Market-cap: USD 1,522.57 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.29 <BR>Return on Equity: -16.06% <BR>Price to Book: 5.40<BR><BR>Contact Details:<BR>Address: 434 FAYETTEVILLE ST., SUITE 1400, RALEIGH NC : 27601 <BR>Tel: 1 646 7479959 <BR>Fax: 1 646 6071776 <BR>Website: https://www.phreesia.com

Read More

Who are in the management team of Phreesia, Inc.?

22-Jun-2025

As of March 2022, the management team of Phreesia, Inc. includes CEO Chaim Indig, Independent Chairman Michael Weintraub, and directors Lainie Goldstein, Dusty Lieb, Edward Cahill, Gillian Munson, and Cheryl Pegus. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Phreesia, Inc. includes the following individuals:<BR><BR>- Mr. Michael Weintraub, Independent Chairman of the Board<BR>- Mr. Chaim Indig, Chief Executive Officer and Director<BR>- Ms. Lainie Goldstein, Director<BR>- Mr. Dusty Lieb, Director<BR>- Mr. Edward Cahill, Independent Director<BR>- Ms. Gillian Munson, Independent Director<BR>- Dr. Cheryl Pegus, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More

Is Phreesia, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Phreesia, Inc. shows a mildly bearish technical trend with underperformance against the S&P 500, reflecting weakness in multiple indicators.

As of 31 October 2025, the technical trend for Phreesia, Inc. has changed from bearish to mildly bearish. The weekly MACD and moving averages are bearish, while the monthly MACD is also bearish. The Bollinger Bands indicate a mildly bearish stance in both weekly and monthly time frames. The KST shows a bearish signal weekly but bullish monthly, while Dow Theory indicates a mildly bearish trend weekly with no trend monthly. <BR><BR>In terms of performance, Phreesia has underperformed the S&P 500 across multiple periods, with a year-to-date return of -10.41% compared to the S&P 500's 16.30%, and a 5-year return of -41.07% versus 109.18% for the index. Overall, the technical stance is mildly bearish, reflecting weakness across several indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a growth in Net Sales of 14.83%, the company declared Very Positive results in Jul 25

  • The company has declared positive results for the last 5 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at USD 51.69 MM
  • ROCE(HY) Highest at -8.76%
  • NET SALES(Q) Highest at USD 117.25 MM
2

High Institutional Holdings at 100%

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Software Products

stock-summary
Market cap

USD 1,609 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.30

stock-summary
Return on Equity

-8.94%

stock-summary
Price to Book

5.40

Revenue and Profits:
Net Sales:
117 Million
(Quarterly Results - Jul 2025)
Net Profit:
1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-34.16%
0%
-34.16%
6 Months
-18.52%
0%
-18.52%
1 Year
-2.88%
0%
-2.88%
2 Years
35.38%
0%
35.38%
3 Years
-28.4%
0%
-28.4%
4 Years
-62.13%
0%
-62.13%
5 Years
-56.86%
0%
-56.86%

Phreesia, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
27.39%
EBIT Growth (5y)
-11.07%
EBIT to Interest (avg)
-67.85
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
1.39
Tax Ratio
7.39%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.67
EV to EBIT
-36.19
EV to EBITDA
-125.10
EV to Capital Employed
7.54
EV to Sales
3.50
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-20.84%
ROE (Latest)
-16.06%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Apr 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 74 Schemes (49.37%)

Foreign Institutions

Held by 104 Foreign Institutions (16.53%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jul'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jul 2025 is 14.89% vs 19.00% in Jul 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jul 2025 is 103.89% vs 51.09% in Jul 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jul'25",
        "Jul'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "117.30",
          "val2": "102.10",
          "chgp": "14.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "6.10",
          "val2": "-9.70",
          "chgp": "162.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.60",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.70",
          "val2": "-18.00",
          "chgp": "103.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-12.90%",
          "val2": "-168.70%",
          "chgp": "15.58%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jan'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jan 2025 is 17.82% vs 26.84% in Jan 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jan 2025 is 57.27% vs 22.26% in Jan 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jan'25",
        "Jan'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "419.80",
          "val2": "356.30",
          "chgp": "17.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-25.30",
          "val2": "-102.80",
          "chgp": "75.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.30",
          "val2": "1.90",
          "chgp": "21.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.80",
          "val2": "-4.20",
          "chgp": "80.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-58.50",
          "val2": "-136.90",
          "chgp": "57.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-131.00%",
          "val2": "-374.30%",
          "chgp": "24.33%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jul'25 - YoYstock-summary
Jul'25
Jul'24
Change(%)
Net Sales
117.30
102.10
14.89%
Operating Profit (PBDIT) excl Other Income
6.10
-9.70
162.89%
Interest
0.40
0.60
-33.33%
Exceptional Items
-0.00
0.00
Consolidate Net Profit
0.70
-18.00
103.89%
Operating Profit Margin (Excl OI)
-12.90%
-168.70%
15.58%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jul 2025 is 14.89% vs 19.00% in Jul 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jul 2025 is 103.89% vs 51.09% in Jul 2024

Annual Results Snapshot (Consolidated) - Jan'25stock-summary
Jan'25
Jan'24
Change(%)
Net Sales
419.80
356.30
17.82%
Operating Profit (PBDIT) excl Other Income
-25.30
-102.80
75.39%
Interest
2.30
1.90
21.05%
Exceptional Items
-0.80
-4.20
80.95%
Consolidate Net Profit
-58.50
-136.90
57.27%
Operating Profit Margin (Excl OI)
-131.00%
-374.30%
24.33%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Jan 2025 is 17.82% vs 26.84% in Jan 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jan 2025 is 57.27% vs 22.26% in Jan 2024

stock-summaryCompany CV
About Phreesia, Inc. stock-summary
stock-summary
Phreesia, Inc.
Software Products
Phreesia, Inc. is a United States-based healthcare software company. The Company provides healthcare organizations a suite of applications to manage the patient intake process and payment solution for patient payments. The Company provides software as a service platform which enables organizations to capture patient records and engage with patients. The Company’s software products enable appointments, registration, revenue cycle, patient surveys, patient activation, analytics and reports, and integration.
Company Coordinates stock-summary
Company Details
434 FAYETTEVILLE ST., SUITE 1400 , RALEIGH NC : 27601
stock-summary
Tel: 1 646 7479959
stock-summary
Registrar Details